CME Group Inc. (CME) $305.11
CME Group’s stock is navigating a complex technical landscape, flashing strong underlying signals even as its immediate upside appears capped, urging investors to WAIT for a more strategic entry.
52-wk High $329.16
📌 Investment Snapshot
- 💰 CME trades at $305.11, commanding a $110.7B market cap with a 27.31x P/E ratio.
- 📈 Latest quarter revenue hit $1.65B, delivering EPS of $3.24, showing consistent performance.
- 🔑 Robust technical confluence score of 90/100 points to underlying strength, despite recent price consolidation.
- 🎯 Analysts maintain a ‘Hold’ consensus with a mean target of $307.50, offering limited immediate upside of just 0.78%.
CME Group’s stock currently sits at $305.11, exhibiting strong technical underpinnings with a 90/100 confluence score, yet its RSI of 43.6 and a meager 0.78% consensus upside suggest it’s not an ideal ‘Buy’ at this precise moment. The stock has rallied significantly over the last three months, now trading above key moving averages, but a recent monthly pullback indicates a cooling-off period.
| 📍 Entry Zone | $295.00 or below | 🛑 Stop-Loss | $285.00 |
| 📋 Adjust If | CME reclaims $310 with strong volume, or if the 10Y Treasury yield breaks below 4.0%. | ||
The Investment Case — Why Now?
Over the past 60-90 days, CME Group has demonstrated impressive resilience, posting a +14.4% return over the last three months. This rally has pushed the stock to 70.2% of its 52-week high, reflecting strong market demand for its offerings amidst a backdrop of moderate volatility (VIX at 23.87) and elevated interest rates (10Y Treasury at 4.31%). The technical confluence score of 90/100 strongly reinforces this underlying strength, highlighting alignment across VWAP, Volume Profile, and Liquidity Sweeps.
However, the immediate investment case faces a critical hurdle: the consensus price target of $307.50 offers a paltry +0.78% upside from current levels. This suggests that much of the near-term growth is already priced in, limiting the potential for significant capital appreciation without a fresh catalyst or a deeper pullback. Furthermore, the stock’s current position above its SMA50 and SMA200, coupled with an RSI of 43.6, indicates it is neither oversold nor presenting a clear high-conviction entry point.
🤔 Given the strong technical signals but limited analyst upside, how much weight should investors place on the technical confluence score versus the consensus price target?
🏢 Company Overview
| Detail | Value |
|---|---|
| Company | CME Group Inc. |
| Ticker / Exchange | CME / NYSE |
| Sector / Industry | Financial Services / Financial Data & Stock Exchanges |
| CEO | Terrence A. Duffy |
| Founded / HQ | 1898 / Chicago, IL |
📈 Price Action & Technicals
Dead Cross
Inside VA
A buy-side sweep at $292.95 on March 31, 2026, indicates recent institutional interest at lower levels.
CME’s price action reveals a stock trading above its key moving averages, with the current price of $305.11 comfortably above the SMA50 ($299.29) and SMA200 ($272.89). This alignment typically signals a bullish trend, supporting the stock’s upward trajectory over the past three months. However, the recent 1-month pullback of -4.3% suggests a period of consolidation or profit-taking.
The technical indicators present a mixed picture. While the RSI at 43.6 remains neutral, the MACD shows a dead cross with the MACD line (-0.86) falling below its signal line (0.54), indicating a potential shift towards bearish momentum. Furthermore, the ADX at 28.7, with a -DI of 25.9 significantly higher than the +DI of 15.1, suggests that bearish trend strength is gaining traction, despite today’s positive price movement.
From a volume perspective, the stock’s current price sits within the Value Area ($252.87-$312.90) and well above the Volume Profile’s Point of Control (POC) at $265.73 and the Anchored VWAP at $270.73. This confirms that the majority of recent trading activity has occurred at lower price levels, implying current prices are at a premium. The volume ratio of 0.81x (below average) on today’s gain could also signal a lack of strong conviction behind the move.
The Bollinger Bands show the price near the middle band, with bands narrowing, often preceding a significant price move. Recent liquidity sweeps, including a buy-side sweep at $292.95, highlight institutional activity around potential support levels. However, unfilled bullish FVGs at $278.25, $270.00, and $262.48 present attractive downside targets if the current price fails to hold, aligning with potential re-entry zones for patient investors.
🤔 Given the conflicting signals from MACD/ADX (bearish) versus the strong technical confluence score and price above SMAs (bullish), which set of indicators should dictate your short-term trading strategy?
⚖ Peer P/E Comparison
| Ticker | Company | P/E (TTM) |
|---|---|---|
| CME | CME Group Inc. | 27.31x |
| ICE | Intercontinental Exchange | 28.5x |
| NDAQ | Nasdaq, Inc. | 25.1x |
| CBOE | Cboe Global Markets | 23.8x |
| S&P 500 | Index Average | 21.0x |
💰 Earnings Deep Dive
| Period | Revenue | EPS | YoY |
|---|---|---|---|
| 2025-12-31 | $1.65B | $3.24 | +7.1% |
| 2025-09-30 | $1.54B | $2.49 | +0.7% |
| 2025-06-30 | $1.69B | $2.81 | +3.7% |
| 2025-03-31 | $1.64B | $2.62 | +2.5% |
CME Group generated a robust $1.1B in Free Cash Flow in the latest quarter, demonstrating strong operational efficiency. The company actively returned capital to shareholders, executing $0.3B in share buybacks during the same period, signaling confidence in its valuation and commitment to shareholder value.
🚀 Growth Drivers — What Moves the Stock
- Market Volatility & Trading Volumes 🟢 Upside Surprise — Elevated market volatility (VIX at 23.87) directly fuels CME’s derivatives trading volumes, driving revenue growth. As macro uncertainties persist, demand for hedging and speculative instruments on CME’s platforms typically increases.
- Interest Rate Environment 🟡 Priced In — The current 10-year Treasury yield at 4.31% benefits CME through higher interest income on its clearing house collateral and increased demand for interest rate futures. A ‘higher for longer’ rate scenario would further support this tailwind.
- Diversification & New Products 🟢 Upside Surprise — CME’s continuous innovation in new product offerings, particularly in areas like crypto derivatives and ESG futures, expands its addressable market and attracts new client segments, fostering long-term growth.
🤔 With the 10Y Treasury yield at 4.31%, do you believe the market has fully priced in the ‘higher for longer’ interest rate narrative for CME, or is there still upside potential from this driver?
🏦 Smart Money & Institutional Positioning
13F Holdings
| Institution | Shares (K) |
|---|---|
| Vanguard Group Inc | 35,895 |
| Blackrock Inc. | 31,077 |
| State Street Corporation | 16,144 |
| JPMORGAN CHASE & CO | 11,101 |
| Geode Capital Management, LLC | 9,327 |
| Morgan Stanley | 8,363 |
| Capital World Investors | 7,278 |
| Price (T.Rowe) Associates Inc | 6,886 |
| NORGES BANK | 5,578 |
| Bank Of New York Mellon Corporation | 4,924 |
Holdings reflect most recent 13F (45-day lag).
Insider Transactions
| Name | Title | Date | Type | Shares |
|---|---|---|---|---|
| SHEPARD WILLIAM R | Director | Mar 26, 2026 | Sale | 1,469 |
| MARCUS JONATHAN L | General Counsel | Mar 17, 2026 | Sale | 3,291 |
| MARCUS JONATHAN L | Officer | Mar 17, 2026 | Sale | 3,291 |
| WINKLER JULIE | Officer | Mar 13, 2026 | Sale | 8,256 |
| CUTINHO SUNIL KIRAN | Chief Technology Officer | Mar 13, 2026 | Sale | 8,256 |
| TOBIN JACK J | Officer | Mar 13, 2026 | Sale | 608 |
| SPRAGUE SUZANNE | Chief Operating Officer | Mar 13, 2026 | Sale | 5,504 |
| FITZPATRICK LYNNE | Chief Executive Officer | Mar 13, 2026 | Sale | 5,504 |
Short Interest
| Short % Float | Days to Cover |
|---|---|
| 0.0% | 2.4 |
⚠ Key Risk Factors
~10-15% Revenue Hit
~5-7% EPS Reduction
~3-5% Margin Compression
Reputational & Operational Risk
🤔 Considering the ‘higher for longer’ rate environment, what specific macro event would most severely challenge CME’s current growth trajectory, and how prepared is the company to mitigate it?
🎯 Guidance & Wall Street View
| High Target | Mean Target | Low Target | Analysts | Consensus |
|---|---|---|---|---|
| $356.00 | $307.50 | $241.00 | 14 | Hold |
| Firm | Rating | Target | Date | Action |
|---|---|---|---|---|
| Argus Research | Hold | Mar 2026 | down | |
| JP Morgan | Underweight | Feb 2026 | main | |
| TD Cowen | Buy | Feb 2026 | main | |
| Barclays | Equal-Weight | Feb 2026 | main | |
| RBC Capital | Sector Perform | Feb 2026 | main | |
| Morgan Stanley | Overweight | Feb 2026 | main | |
| Morgan Stanley | Overweight | Jan 2026 | main | |
| TD Cowen | Buy | Jan 2026 | up |
The analyst consensus for CME Group is a ‘Hold,’ with a mean price target of $307.50, implying minimal upside from the current price. This reflects a cautious stance, suggesting that while the company’s fundamentals are sound, the stock’s current valuation may already incorporate much of its near-term growth potential.
📊 Bull vs Bear — Probability-Weighted Scenarios
🐂 Bull Case
- Sustained market volatility and high interest rates continue to drive robust trading volumes and interest income for CME.
- CME’s strong technical confluence score (90/100) suggests underlying institutional support, with potential for a bounce from key support levels.
📊 Base Case
Our base case assumes CME maintains its strong market position and benefits from moderate market volatility and stable interest rates. The stock’s valuation remains fair, aligning with the current analyst consensus. We expect continued share buybacks to provide a floor.
🐻 Bear Case
- A sharp decline in market volatility or a rapid reversal in interest rate policy significantly reduces CME’s core revenue streams.
- Technical breakdown below SMA200 ($272.89) or a failure to fill open FVGs, triggering further downside towards the low end of analyst targets.
🎯 Investor Action Plan — By Profile
Swing traders should AVOID CME at current levels due to the conflicting technical signals and limited immediate upside. Wait for a clear break above $310 with above-average volume, or a pullback to the $290-$295 range (near SMA50 and recent buy-side sweep) for a potential bounce play, with a tight stop below $285.
Position investors should WAIT for a more attractive entry. While the underlying technical strength is compelling, the current valuation and low consensus upside make it less appealing. Consider scaling into a position if CME pulls back towards the $270-$280 range, aligning with the Anchored VWAP and unfilled bullish FVG zones, establishing a stop-loss at $260.
Long-term investors already holding CME should HOLD their positions. The company’s robust business model, consistent cash flow, and strategic position in global financial markets remain intact. Continue to monitor macro trends and earnings reports, but the core thesis for long-term growth remains solid.
❓ Investor FAQ — People Also Ask
Q: Why is CME’s technical confluence score so high (90/100) if the verdict is ‘WAIT’?
The high technical confluence score indicates strong underlying technical structure, with alignment across VWAP, Volume Profile, and Liquidity Sweeps. However, a ‘WAIT’ verdict is issued because other critical criteria for a ‘BUY’ are not met, specifically the RSI (43.6, not oversold) and the consensus target (only +0.78% upside), suggesting the stock is not at an ideal entry point despite its technical strength.
Q: What are the key price levels to watch for a potential entry into CME?
For a more strategic entry, closely monitor the $290-$295 range, which aligns with the SMA50 and a recent buy-side liquidity sweep. Deeper pullbacks to the $270-$280 zone, corresponding to the Anchored VWAP ($270.73) and several unfilled bullish FVG zones, would present even higher-conviction entry opportunities for patient investors.
Q: How do the insider sales impact the investment thesis for CME?
Recent insider transactions show multiple officers and directors selling shares in March 2026. While these could be routine liquidity events or option exercises, a consistent pattern of insider sales, especially without corresponding purchases, can signal that those closest to the company perceive the stock as fairly valued or even overvalued at current levels, adding a layer of caution to the investment thesis.
📊 How has the stock moved since this analysis?
📋 Disclaimer
This analysis is for informational purposes only and does not constitute financial advice. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. Past performance is not indicative of future results. All data is accurate as of April 5, 2026.
All active positions and their real-time performance are tracked on our Investment Log.
#CME #CMEGroup #USStocks #StockAnalysis #FinancialServices #Derivatives #MarketData #Veqtio